Angel Biotech delivers another blow as it calls in administrators

Angel Biotechnology, which makes stem cells for medical research, delivered another blow to investors on Friday, calling for trading of shares to be suspended and sending the share price down over nine per cent.

Angel Biotechnology, which makes stem cells for medical research, delivered another blow to investors on Friday, calling for trading of shares to be suspended and sending the share price down over nine per cent.

The company, which in January announced that it was in discussions with a consortium of overseas organisations with the aim of establishing a strategic relationship between both parties in order to more effectively develop its contract manufacturing business, said Friday that these discussions have ended.

As a result the company has requested the immediate suspension of trading of its shares on AIM, pending clarification of its financial position.

"In view of its trading difficulties, the company intends to appoint administrators and a further announcement will be made as appropriate," was the comment made by the firm.

At the end of January the group said that the future of the group was dependent on it delivering both the proposed joint venture with MMH, but also on it entering a strategic relationship with another party.

It also acknowledged that it would be "extremely difficult" to raise funds through the market at the present time.

Angel, which makes stem cells for medical research, posted wider half year losses at £2.86m for the six month period ended September 30th 2012, most of which is attributable to a write back of accrued revenue and contract liabilities related to joint ventures. The company posted a loss of £241,000 the year before. Revenue for the period slipped to £1.07m from £1.4m previously.

Recommended

The top funds to invest in
Funds

The top funds to invest in

Investors continue to favour passive funds in April though figures reveal an actively managed money market fund also caught their eye. We look at wher…
3 May 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
20 Apr 2023
Best junior stocks and shares ISA platforms
Isas

Best junior stocks and shares ISA platforms

A junior stocks and shares ISA is a great way to save for your child tax-efficiently. But it can be confusing deciding which investment platform to ch…
28 Mar 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023

Most Popular

June’s NS&I Premium Bond prize draw - are you this month’s millionaire?
Savings

June’s NS&I Premium Bond prize draw - are you this month’s millionaire?

Two fortunate NS&I Premium Bond winners are now millionaires. Find out here if you’re one of them.
1 Jun 2023
Housing slowdown ‘deeper than anticipated’ as property sales slump
House prices

Housing slowdown ‘deeper than anticipated’ as property sales slump

New data from HMRC shows a fall in property sales - now experts predict a delay to the housing recovery
1 Jun 2023
The best one-year fixed savings accounts - June 2023
Savings

The best one-year fixed savings accounts - June 2023

You can now earn 5% on 1 year fixed savings accounts - the best rate seen in 14 years. We have all the latest rates available now.
2 Jun 2023